These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9402746)

  • 21. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia.
    Horácek JM; Pudil R; Tichý M; Jebavý L; Strasová A; Praus R; Zák P; Malý J
    Neoplasma; 2005; 52(5):430-4. PubMed ID: 16151589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
    Liu Y; Ke XY; Ma J; Shen ZX; Zhang XH; Du X; Zhao YM; Lv JQ; Zhan ZM; Zeng XY; Xu XH; Lu ZS
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):706-8. PubMed ID: 17274381
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patients.
    Olivieri A; Capelli D; Troiani E; Poloni A; Montanari M; Offidani M; Discepoli G; Leoni P
    Exp Hematol; 2007 Jul; 35(7):1074-82. PubMed ID: 17588476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
    Bengala C; Danesi R; Guarneri V; Pazzagli I; Donati S; Favre C; Fogli S; Biadi O; Innocenti F; Del Tacca M; Mariani M; Conte PF
    Bone Marrow Transplant; 2003 Feb; 31(4):275-80. PubMed ID: 12621462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
    Russo D; Malagola M; de Vivo A; Fiacchini M; Martinelli G; Piccaluga PP; Damiani D; Candoni A; Michielutti A; Castelli M; Testoni N; Ottaviani E; Rondoni M; Pricolo G; Mazza P; Zuffa E; Zaccaria A; Raspadori D; Bocchia M; Lauria F; Bonini A; Avanzini P; Gugliotta L; Visani G; Fanin R; Baccarani M
    Br J Haematol; 2005 Oct; 131(2):172-9. PubMed ID: 16197446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The combination regimen of idarubicin and taxotere is effective against human drug-resistant leukemic cell lines.
    Majlessipour F; Avramis IA; Kwock R; Weinberg KI; Avrami VI
    Anticancer Res; 2002; 22(3):1361-8. PubMed ID: 12168812
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results.
    Pigneux A; Perreau V; Jourdan E; Vey N; Dastugue N; Huguet F; Sotto JJ; Salmi LR; Ifrah N; Reiffers J
    Haematologica; 2007 Oct; 92(10):1327-34. PubMed ID: 18024370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology.
    Matsouka P; Pagoni M; Zikos P; Giannakoulas N; Apostolidis I; Asprogeraka T; Arvanitopoulou E; Spanoudakis E; Kotsianidis I; Tsatalas K; Papaioannou M; Marinakis T; Skandali A; Viniou N; Yataganas X; Bakiri M
    Ann Hematol; 2006 Apr; 85(4):250-6. PubMed ID: 16416114
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral treatment of acute myeloid leukaemia with etoposide, thioguanine, and idarubicin (ETI) in elderly patients: a prospective randomised comparison with intravenous cytarabine, idarubicin, and thioguanine in the second and third treatment cycle.
    Ruutu T; Koivunen E; Nousiainen T; Pelliniemi TT; Almqvist A; Anttila P; Jantunen E; Koistinen P; Koponen A; Mikkola M; Oksanen K; Pulli T; Remes K; Sarkkinen R; Silvennoinen R; Timonen T; Vanhatalo S; Elonen E;
    Eur J Haematol; 2004 Jan; 72(1):38-44. PubMed ID: 14962261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A single high dose of idarubicin combined with high-dose ABA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University La Sapienza of Rome.
    Testi AM; Moleti ML; Giona F; Annino L; Chiaretti S; Del Giudice I; Todisco E; D'Elia G; Ferrari A; Arcese W; Mandelli F
    Haematologica; 1997; 82(5 Suppl):19-22. PubMed ID: 9402749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.
    Stone RM; DeAngelo DJ; Janosova A; Galinsky I; Canning C; Ritz J; Soiffer RJ
    Am J Hematol; 2008 Oct; 83(10):771-7. PubMed ID: 18756547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New oral drugs in older patients: a review of idarubicin in elderly patients.
    Crivellari D; Lombardi D; Spazzapan S; Veronesi A; Toffoli G
    Crit Rev Oncol Hematol; 2004 Feb; 49(2):153-63. PubMed ID: 15012975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia.
    Szmigielska-Kaplon A; Smolewski P; Najder M; Robak T
    Ann Hematol; 2002 Sep; 81(9):508-13. PubMed ID: 12373351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A pilot study of oral idarubicin in metastatic melanoma.
    Martoni A; Pacciarini MA; Piana E; Pannuti F
    Chemioterapia; 1986 Dec; 5(6):414-5. PubMed ID: 3467876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.
    Garcia-Manero G; Faderl S; Giles F; Thomas D; Cortes J; O'Brien S; Davis J; Kantarjian HM; Estey E
    Haematologica; 2002 Aug; 87(8):804-7. PubMed ID: 12161355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.
    Clavio M; Gatto S; Beltrami G; Quintino S; Canepa L; Pierri I; Galbusera V; Carrara P; Miglino M; Varaldo R; Ballerini F; Venturino C; Cerri R; Risso M; Balleari E; Carella AM; Sessarego M; Ghio R; Bacigalupo A; Gobbi M
    J Exp Clin Cancer Res; 2002 Dec; 21(4):481-7. PubMed ID: 12636093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment].
    Rodríguez JN; Fernández-Jurado A; Martino ML; Diéguez JC; Moreno MV; Quesada JA; Polo B; Cañavate M; Amian A; Prados D
    Sangre (Barc); 1998 Feb; 43(1):35-9. PubMed ID: 9580427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia.
    Pea F; Damiani D; Michieli M; Ermacora A; Baraldo M; Russo D; Fanin R; Baccarani M; Furlanut M
    Eur J Clin Pharmacol; 1999 Jul; 55(5):361-8. PubMed ID: 10456485
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multidrug reverting activity toward leukemia cells in a group of new verapamil analogues with low cardiovascular activity.
    Biscardi M; Teodori E; Caporale R; Budriesi R; Balestri F; Scappini B; Gavazzi S; Grossi A
    Leuk Res; 2006 Jan; 30(1):1-8. PubMed ID: 16061283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.